Skip to main content
Contact Us
Subscribe
E-Edition
45°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Bio-Path Holdings, Inc.
Bio-Path Holdings Reports Full Year 2023 Financial Results
March 08, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024
March 01, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces 1-for-20 Reverse Stock Split
February 21, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Completion of First Dose Cohort in Phase 1 Clinical Trial Evaluating BP1002 to Treat Refractory/Relapsed Lymphoma and Refractory/Relapsed Chronic Lymphocytic Leukemia Patients
January 10, 2024
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Successfully Completes First Dose Cohort of Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia
December 14, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Third Quarter 2023 Financial Results on November 15, 2023
November 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia
October 24, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Second Quarter 2023 Financial Results
August 15, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Second Quarter 2023 Financial Results on August 15, 2023
August 08, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings, Inc. Announces Pricing of $2.1 Million Public Offering
August 03, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
August 01, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces Successful Completion of First Dose Cohort in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
July 17, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports First Quarter 2023 Financial Results
May 12, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
May 05, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Full Year 2022 Financial Results
March 31, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
March 24, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Provides Clinical and Operational Update
March 16, 2023
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors
December 07, 2022
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Reports Third Quarter 2022 Financial Results
November 15, 2022
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
November 08, 2022
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement
November 07, 2022
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients
October 24, 2022
From
Bio-Path Holdings, Inc.
Via
GlobeNewswire
Tickers
BPTH
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.